jack14 Posted September 19, 2021 Share Posted September 19, 2021 I just learned from my Oncologist that they (her and a consulting Onc who has recently published a paper on MET Amplification) have determined that Crizotnib is more likely to be effective if the mutation has ten or more copies. Also, the side effects that Crizotnib has are usually less troublesome if it is used before immunotherapy rather than after it. This is what my understanding is anyway after hearing it third person. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.